Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status by Skates, Steven J. et al.
Large Prospective Study of Ovarian Cancer Screening in High-
risk Women: CA125 Cut-point Defined by Menopausal Status
Steven J. Skates1, Phuong Mai2, Nora K. Horick1, Marion Piedmonte3, Charles W.
Drescher4, Claudine Isaacs5, Deborah K. Armstrong6, Saundra S. Buys7, Gustavo C.
Rodriguez8, Ira R. Horowitz9, Andrew Berchuck10, Mary B. Daly11, Susan Domchek12,
David E. Cohn13, Linda Van Le14, John O. Schorge15, William Newland16, Susan A.
Davidson17, Mack Barnes18, Wendy Brewster19, Masoud Azodi20, Stacy Nerenstone21,
Noah D. Kauff22, Carol J. Fabian23, Patrick M. Sluss24, Susan G. Nayfield25,26, Carol H.
Kasten25,27, Dianne M. Finkelstein1, Mark H. Greene2, and Karen Lu28
1 Biostatistics Department, Massachusetts General Hospital, Boston MA
2 Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer
Institute, Bethesda MD
3 GOG Statistical and Data Center, Roswell Park Cancer Institute, Buffalo NY
4 Department of Gynecology, Swedish Medical Center, Seattle WA
5 Department of Medicine and Oncology, Lombardi Comprehensive Center, Georgetown
University, Washington D.C
6 Oncology, Gynecology and Obstetrics, Johns Hopkins Kimmel Cancer Center, Baltimore MD
7 Hematology and Oncology, Huntsman Cancer Institute, Salt Lake City UT
8 NorthShore University Health System, Evanston, Northwestern Healthcare, Evanston IL
9 Winship Cancer Institute, Emory University School of Medicine, Atlanta GA
10 Department of Obstetrics and Gynecology, Duke Comprehensive Cancer Center, Durham NC
11 Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia PA
12 Abramson Cancer Center, University of Pennsylvania, Philadelphia PA
13 Division of Gynecologic Oncology, James Cancer Hospital and Solove Research Institute, Ohio
State University College of Medicine, Columbus OH
14 Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill NC
15 Gynecologic Oncology, Massachusetts General Hospital, Boston MA
16 Department of Obstetrics and Gynecology, John Stoddard Cancer Center, Iowa Methodist
Medical Center, Des Moines IA
17 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of
Colorado Denver, Aurora CO
18 Gynecology and Oncology, University of Alabama, Birmingham AL
19 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of
California Irvine School of Medicine, Orange CA
Corresponding Author: Dianne Finkelstein, 50 Staniford Street, Suite 560, Boston, MA 02114, dfinkelstein@partners.org.
NIH Public Access
Author Manuscript
Cancer Prev Res (Phila). Author manuscript; available in PMC 2012 September 1.
Published in final edited form as:













20 Department of Obstetrics and Gynecology. Division of Gynecologic Oncology, Yale University,
New Haven CT
21 Central Connecticut Cancer Consortium, Hartford Hospital, Hartford CT
22 Clinical Genetics and Gynecology Services, Memorial Sloan-Kettering Cancer Center, New
York NY
23 The University of Kansas Cancer Center, Westwood KS
24 Clinical Pathology Core Laboratories, Massachusetts General Hospital, Boston MA
25 Epidemiology and Genetics Research Program, Division of Cancer Control and Prevention
Sciences, National Cancer Institute, Bethesda MD
26 Department of Aging and Geriatric Research, Institute on Aging, College of Medicine,
University of Florida, Gainesville FL
27 Office of the Director, Eunice Kennedy Shriver National Institute for Child Health & Human
Development, Bethesda MD
28 Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD
Anderson Cancer Center, Houston TX
Abstract
Background—Previous screening trials for early detection of ovarian cancer in postmenopausal
women have used the standard CA125 cut-point of 35 U/mL, the 98th percentile in this population
yielding a 2% false positive rate, while the same cut-point in trials of premenopausal women
results in substantially higher false positive rates. We investigated demographic and clinical
factors predicting CA125 distributions, including 98th percentiles, in a large population of high-
risk women participating in two ovarian cancer screening studies with common eligibility criteria
and screening protocols.
Methods—Baseline CA125 values and clinical and demographic data from 3,692 women
participating in screening studies conducted by the NCI-sponsored Cancer Genetics Network and
Gynecologic Oncology Group were combined for this pre-planned analysis. Due to the large effect
of menopausal status on CA125 levels, statistical analyses were conducted separately in pre- and
postmenopausal subjects to determine the impact of other baseline factors on predicted CA125
cut-points based on the 98th percentile.
Results—The primary clinical factor affecting CA125 cut-points was menopausal status, with
premenopausal women having a significantly higher cut-point of 50 U/mL while in
postmenopausal subjects the standard cut-point of 35 U/mL was recapitulated. In premenopausal
women, current oral contraceptive (OC) users had a cut-point of 40 U/mL.
Conclusions—To achieve a 2% false positive rate in ovarian cancer screening trials and in high-
risk women choosing to be screened, the cut-point for initial CA125 testing should be personalized
primarily for menopausal status (~ 50 for premenopausal women, 40 for premenopausal on OC, 35
for postmenopausal women).
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CA125 is currently used primarily to monitor ovarian cancer patients during chemotherapy
and as a biomarker for early detection of recurrence. In these settings, the cut-point of 35 U/
mL for a positive test has often been the standard, as recommended by Bast and colleagues
(1). This cut-point was determined by studying 800 healthy blood center donors, and finding
that 98% of CA125 values were below 35 U/mL; in contrast, 80% of measurements from
ovarian cancer cases were above 35 U/mL. Given this possible discrimination between
patients with ovarian cancer and controls, CA125 has also been used as a first-line test in
multiple ovarian cancer screening trials. For general population screening, the target
population has most often been postmenopausal women, since this is the group in which
most ovarian cancers occur. The initial use of CA125 as an ovarian cancer screening test
was modeled on the clinical test for detection of cancer recurrence, namely a fixed cut-point
usually at the reference level of 35 U/mL. Of three large ovarian cancer screening trials in
postmenopausal women (2–4), and one in premenopausal women(5), three used cut-points
of 35 U/mL and one used 30 U/mL(3), the latter choice due to concern about CA125’s poor
sensitivity for detecting early stage disease. However, while this cut-point may be
appropriate in general, there are sub-groups of patients in which the 98th percentile differs
significantly from 35 U/mL, wherein a different cut-point may be appropriate. Limited
information is available, though, regarding the characteristics of these subgroups or the
appropriate cut-points for particular subgroups.
Further, determination of these cut-points has become particularly relevant with the
discovery of BRCA1 and BRCA2 since we can now identify a sub-group of women with a
markedly increased annual incidence of ovarian cancer, approaching as high as 1% per year.
Several screening trials are currently being conducted in women at high risk of, or known to
carry, a deleterious mutation in BRCA1 or BRCA2.(5–8) In these trials, a significant
proportion of women were premenopausal due to the younger-than-usual age-at-diagnosis
for BRCA-related ovarian cancer. CA125 is known to have a high false positive rate amongst
premenopausal women using the 35 U/mL cut-points. This is particularly relevant in a high
risk population given the anxiety related to false positive results. As reported in one trial, (8)
there was significant anxiety reported due to false positive CA125 results.
Defining cut-points based on factors predicting the CA125 distribution is a first step towards
personalizing the screening test for each woman entering a screening trial. This report
identifies factors that influence predicted CA125 blood levels through analyses of baseline
data from two large prospective trials in high risk women, and provides CA125 cut-points
for specific sub-groups of women. These cut-points can be used for high risk women
choosing screening rather than risk-reducing surgery to manage their ovarian cancer risk,
and in future ovarian cancer screening trials in high risk women.
Materials and Methods
The Cancer Genetics Network, an NCI-funded network for research on inherited
malignancies, initiated an ovarian cancer screening pilot strategy for women at increased
genetic risk in 2001. (9) Eligible women were at high risk of ovarian and breast cancer due
to either two or more breast and ovarian cancers, or a BRCA1 or BRCA2 mutation, in first-
and/or second degree blood relatives, with breast cancer in the subject counting towards the
total. The screening strategy implemented ROCA (risk of ovarian cancer algorithm) based
on longitudinal CA125 values (10) from every three month testing with referral to trans-
vaginal sonography (TVS) for an intermediate risk of having ovarian cancer, and TVS and
review by a gynecologic oncologist for an elevated risk. Two other NCI programs, the
ovarian Specialized Programs of Research Excellence (SPORE), and the Early Detection
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Research Network (EDRN), as well as five independent clinical sites subsequently joined
the trial and contributed subjects. There were 2,352 high-risk women enrolled in the study at
25 US sites. The aim of the study was to provide the first assessment of the operating
characteristics of ROCA in high-risk women and to evaluate the acceptability of a screening
protocol requiring every 3 month blood tests. At study entry, participants filled out a
baseline questionnaire with demographic, menstrual and reproductive history, personal
history of cancer and cancer treatment, use of tobacco, alcohol, caffeine, talc, and exposure
to x-rays, medications (including hormones), abdominal symptoms, and family cancer
history. Two years after the CGN study began, the Gynecologic Oncology Group (GOG)
initiated a two-arm, non-randomized natural history study of high-risk women choosing
between risk reducing salpingo-oophorectomy (RRSO) and screening. (6) The GOG study
eligibility criteria and screening algorithm were the same as for the CGN study, (with the
exception that patients having had prior bilateral oophorectomy were ineligible for the GOG
study) enabling data to be compared across the two studies. Incidentally, the two cohorts
provided an estimate of the proportion of high-risk women (defined identically in the two
studies) who had undergone clinical testing for deleterious germline mutations in BRCA1/
BRCA2, i.e., 27% (986/3692), prior to study entry. Thus, the majority of women entered
these screening trials without knowing their BRCA mutation status. With 1442 women
enrolled in the GOG study, baseline data from 3,794 women were available for statistical
modeling, providing a rich source for sub-group analysis of CA125 distributions and
determinations of sub-group specific cut-points (98th percentiles). Factors which a priori
were expected to contribute to prediction of CA125 levels include menopausal status, (11)
number of ovaries, race, (12) presence of uterus, (13) and age.
Of the 3,794 women recruited to the combined CGN/GOG study, subjects who were
ineligible after enrollment and those missing either a baseline CA125 measurement or the
baseline questionnaire were excluded. In addition, subjects who were diagnosed with
ovarian cancer after enrollment were excluded. This process provided analyzable baseline
data from 3,692 women; 2,251 women enrolled in the CGN study and 1,441 women
enrolled in the GOG study. All peripheral blood samples for both studies were collected
from venepunctures in 10mL red top glass tubes [no additives or clotting enhancers],
immediately spun down and the serum frozen at −80°C prior to batch shipping on dry ice, or
individually shipped overnight wrapped in foam on a frozen ice pack in a Styrofoam
container, to the central lab. All serum CA125 values were measured at the Reproductive
Endocrine Unit Reference Laboratory at Massachusetts General Hospital on a Roche
Elecsys immunoanalyzer, initially an Elecsys-2010, and then an E170 in 2006. The
reportable range of the assay is 0.6 – 500 IU/mL, with a normal reference interval for
females of < 35 U/mL. Grossly hemolyzed or lipemic specimens were rejected and not
tested, and a replacement blood draw requested. Assay CV on the E170 automated
instrument is < 4% based on daily monitoring with quality control (QC) specimens (low QC
mean = 32 U/mL, high QC mean = 93 U/mL). Preliminary univariate analyses were
conducted to determine the association between each baseline variable and log-transformed
CA125 values. Standard statistical methods based on Normal distributions (e.g. linear
regression, ANOVA) are more appropriate for the log-CA125 scale since the distribution of
log(CA125) values far more closely resembles a symmetric bell-shaped curve than the very
skew distribution of the non-transformed CA125 values. Statistical analyses of log-CA125
can be readily interpreted on the original CA125 scale by noting that to first order,
percentage changes on the original CA125 scale (e.g. 10% change) are estimated by the
factor effects (e.g. 0.1 change in log-CA125), median CA125s are estimated by
exponentiated means from the log-CA125 scale, and the estimate of CV (coefficient of
variation) (e.g. 20% CV) is the standard deviation (SD) on the log-CA125 scale (e.g. SD of
0.2).
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It is well known that the CA125 distribution is strongly affected by menopausal status. (11)
Following confirmation of a very significant univariate difference in CA125 levels between
pre and postmenopausal women in this cohort, subjects were grouped according to
menopause status, and all subsequent analyses were conducted separately within pre- and
postmenopausal groups. A subject was designated as postmenopausal if: 1) more than a year
elapsed since their last menstrual period (LMP) at time of baseline blood draw, or 2) if the
LMP date was not reported, the subject indicated their period had stopped for at least a
duration of three regular cycles, or 3) if there were no data to determine either of the above
criteria, age exceeded 50. Missing values were replaced with “no” responses for categorical
factors and with the median values for continuous variables. The potential bias introduced
by this method for handling missing values is towards the null hypothesis of no effect,
which results in a decreased likelihood that a given variable will be significantly associated
with baseline CA125. This effect will be small since the percentage of missing values was
very low, ranging from less than 1% for age to 7% for number of ovaries in postmenopausal
women. Age defined menopausal status in only 2.6% of subjects, for all other subjects
menopausal status was directly known. The preliminary univariate analyses compared log-
CA125 across groups using analysis of variance (ANOVA) for categorical variables and
computed Pearson correlations for continuous variables. The standard deviation of log-
CA125 values was consistently close to 0.5 across different sub-groups, equivalent to a
CA125 CV of 50% between women within a sub-group, which supported the constant
variance assumption of ANOVA. Variables that were significant (P < 0.1, by either
ANOVA or Pearson ρ) in the preliminary univariate analyses were included in the initial
multiple linear regression model. The factor with the least non-significant effect was
removed, the model re-fitted, and the process iterated, until only variables with a significant
impact on log-CA125 remained. Two-factor interactions for final main effects were fully
examined but even though two were statistically significant in premenopausal women they
were not included in the final model due to the very small within sub-population sample
sizes (black women who smoked n=6, and Asian women with irregular periods n=9). The
final model estimated coefficients for the predictors of the CA125 distribution. To provide
estimates on the CA125 scale, the median CA125 for each subgroup was estimated from
exp(mean log-CA125), and the 98th percentile from exp(2.05 SDs + mean log-CA125)
(mean specific to the sub-group, SD estimate pooled across sub-groups). A quadratic term
for age was included to account for potential non-linearity in the effect of age. For
comparison, a standard reference group of baseline factors was defined for pre- and
postmenopausal subjects. Generally, the standard profile reflected a woman with “no”
responses for each factor (i.e. “unexposed” to the factors that affect baseline CA125) and
whose values for continuous variables such as age are set at fixed values. For premenopausal
women, the reference group consisted of 50-year-old women from the CGN study cohort
who were white, had regular menstrual periods, and were not current users of oral
contraceptives or cigarettes. The reference group in postmenopausal subjects corresponded
to 50-year-old women from the CGN study cohort who were white, had two intact ovaries,
had never used fertility drugs, were not current smokers, and who experienced menopause at
age 45. Median and cut-point CA125 estimates for a factor reflect the estimated change in
CA125 for a subgroup defined by changing the factor compared with the standard profile.
Changes were considered statistically significant if the p-value was less than 0.05. However,
while some changes could be statistically significant due to the relatively large sample size,
these differences could be of sufficiently small magnitude that they would be unlikely to be
of major clinical significance. Changes were considered of minor clinical importance if the
change was less than 10%.
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The univariate 98th percentile CA125 cut-point amongst premenopausal women in this study
was 49 U/mL. Amongst postmenopausal women the CA125 cut-point was 34 U/mL, which
recapitulated the standard cut-point for CA125 of 35 U/mL. Table 1 presents the factors,
cut-points, median, sample sizes, and the p-value for the difference within factor levels,
stratified by menopausal status. Only factors with a univariate statistical significance (p ≤
0.1) for CA125 in either pre- or postmenopausal subjects or both are displayed in Table 1.
The effect estimates in Table 1 reflect no adjustment for the impact of other factors.
Premenopausal women in the reference group had a 98th percentile cut-point of 52 U/mL for
CA125 in the multivariate analysis, significantly higher than 36 U/mL in postmenopausal
women in the reference group (P < 0.0001). Due to the large impact of menopausal status,
the effects of other factors were examined within each menopausal group. Table 2
summarizes the factors that were significant in the multivariate linear models in pre- and
postmenopausal subjects, adjusting for the presence of multiple factors simultaneously. As
in the univariate analyses, the value of 36 U/mL recapitulated the standard clinical cut-point
of 35 U/mL for postmenopausal women, as expected. Several factors (e.g., hormone
replacement therapy, BRCA1 and BRCA2 mutation status, family history of ovarian cancer,
and hysterectomy) were significant in the univariate analysis but no longer significant in the
multivariate analysis. This is likely due to confounding between these variables and other
factors that had a stronger correlation with CA125 values. Analyses of risk categories (low,
intermediate, and mutation carrier) given family history may refine this conclusion but
require collection of detailed pedigrees not available in this study.
Results of Secondary Factors in Premenopausal Women
Based on the univariate results, current use of oral contraceptives was associated with a
large and significant reduction in CA125, with the 98th percentile cut-point of 39 U/mL
among current users. Other factors associated with a statistically significant (although
smaller) reduction in CA125 among premenopausal women in the univariate analyses
include former or current smoking (cut-points: 43 U/mL and 48 U/mL, respectively),
irregular periods (cut-point: 44 U/mL), Ashkenazi Jewish heritage (cut-point: 47 U/mL), and
presence of a (self-reported) deleterious BRCA1 or BRCA2 mutation (cut-point: 46 U/mL).
Premenopausal women with a family history of ovarian cancer had a clinically minor but
statistically significant reduction in CA125 (cut-point: 48 U/mL) compared with women
who reported no ovarian cancer family history (cut-point: 50 U/mL). CA125 among
premenopausal women of Asian descent was significantly lower (cut-point: 38 U/mL)
compared with women of other ancestry. Finally, the univariate analyses suggested that
women in the GOG cohort had a lower CA125 cut-point (47 U/mL) compared with women
in the CGN cohort (51 U/mL).
The effects of each factor listed in the middle column within menopausal groups (pre-,
post-) of Table 2 comprise the important estimates from the multivariate analysis, since
these estimates enable the joint effect of any combination of factors to be estimated. Current
use of oral contraceptives in premenopausal women had the greatest impact on predicted
CA125 levels, with levels 26% lower than those who were not currently using oral
contraceptives (P < 0.0001). Premenopausal women with Asian background had CA125
levels that were 24% lower than non-Asians (P = 0.009). CA125 levels were 15% lower in
premenopausal current smokers than in non-smokers (P = 0.0003). Having irregular periods
corresponded to an 11% decline in CA125 values compared with those reporting regular
cycles (P = 0.01). Premenopausal women in the GOG cohort had CA125 levels that were, on
average, 7% lower compared with women in the CGN cohort (P = 0.002).
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Considering a premenopausal oral contraceptive user of non-Asian descent who is a current
smoker with irregular cycles provides an example of the additive effect of multiple factors
on predicted CA125 levels. The individual effects of these factors were reductions of 26%,
15% and 11%, respectively (Table 2). For a premenopausal woman with all these factors,
the reduction is the sum of these values, namely 52%, reducing the CA125 cut-point from 52
U/mL to 25 U/mL. This demonstrates the large change in cut-point due to the cumulative
effect of multiple secondary factors.
Results of Secondary Factors in Postmenopausal Women
Among postmenopausal women, the univariate results suggest that several factors are
associated with a significant reduction in CA125, compared with the overall 98th percentile
cut-point of 34 U/mL. These include prior use of fertility treatment (cut-point: 28 U/mL),
African-American race (cut-point: 27 U/mL), and prior removal of both ovaries (cut-point:
30 U/mL). Hysterectomy was associated with a very subtle clinical effect, but statistically
significant reduction of about 2 U/mL in the CA125 cut-point in postmenopausal women.
As was found in premenopausal women, postmenopausal women in the GOG cohort have a
significantly lower CA125 cut-point (31 U/mL) compared with postmenopausal members of
the CGN cohort (34 U/mL).
Based on results from the multivariate model as summarized by the right hand columns of
Table 2, the estimated CA125 cut-point among postmenopausal women in the reference
group (i.e., women with “no” responses for all significant categorical factors, with current
age and age at menopause equal to 50 and 45, respectively) was 36 U/mL. Compared with
this profile, postmenopausal black women had a 22% reduction in predicted CA125 levels
(P = 0.0008), and having had prior oophorectomy or prior use of fertility drugs reduced
predicted CA125 levels by 18% and 17%, respectively (P < 0.0001, P = 0.01); removal of
one ovary had no impact. The association with current smoking was not as pronounced in
postmenopausal women; the 8% reduction just reached statistical significance. Age at
menopause and current age had statistically significant but clinically marginal effects.
Factors identified by our study and predictive of CA125 levels amongst normal risk
postmenopausal women in a UK study(12) were African ethnicity, Asian ethnicity,
hysterectomy, regular smoking, age at menopause, and current age. Women from the GOG
study group had 13% lower CA125 levels (P < 0.0001). Considering a current smoker with
previous use of fertility drugs provides an example of the additive effect of multiple factors
in postmenopausal women. The individual effects of these two factors were reductions of
8% and 17%, respectively. For a postmenopausal woman with both these factors, the
reduction was the sum of these two values, namely 25%, reducing the cut-point from 36 U/
mL to 27 U/mL.
Discussion
Our demonstrating significant differences in median CA125 levels and 98th percentile
CA125 cut-points between the pre and postmenopausal reference groups and specific sub-
groups indicates that the choice of 35 U/mL as a global cut-point in women undergoing
ovarian cancer screening needs to be reconsidered. The strongest primary clinical effect was
due to menopausal status, with premenopausal women in the reference group having a
significantly higher cut-point of 52 U/mL compared with the standard 35 U/mL for the
postmenopausal reference group, and 40 U/mL for premenopausal women on OC.
While it is well known that premenopausal women have higher levels of CA125 than
postmenopausal women, the analysis reported herein provides the best available
quantification of this aspect of CA125 interpretation. A reference level of about 50 U/mL is
equivalent in premenopausal women to a reference level of 35 U/mL in postmenopausal
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women, in that 2% of premenopausal women without ovarian cancer will have levels
exceeding 50 U/mL resulting in similar false positive rates in premenopausal women as in
postmenopausal women. In one study with approximately equal numbers of pre- and
postmenopausal women, premenopausal women had significantly higher anxiety than
postmenopausal women, and two premenopausal women withdrew from screening due to
anxiety from false positive CA125 results.(8) Whether this higher threshold for post-
screening workups should be used for premenopausal women requires balancing multiple
clinical considerations, such as the lower rate of false positive CA125 results which may
reduce ovarian cancer risk-related anxiety,(8) the lower sensitivity expected for ovarian
cancer cases due to a higher cut-point, and the larger number of years of life lost by a
premenopausal woman who experiences early death due to ovarian cancer than for the
postmenopausal woman. In this context, it is rational (albeit not yet proven worthwhile) to
provide equivalent CA125 cut-points for premenopausal women rather than the standard
used for postmenopausal women. At present, pre- and postmenopausal high-risk women are
both managed using the 35 U/mL cut-point. Our data suggest that, at the very least, the use
of the standard CA 125 cut-point in premenopausal women is likely to cause a high false-
positive screening rate, as a consequence of ignoring factors that predict higher baseline CA
125 levels.
Relative to menopausal status, factors of secondary clinical importance defined multiple
sub-groups in which clinically and statistically significant differences in the CA125 cut-
point were observed. Applying sub-group specific CA125 cut-points would individualize the
screening test for the initial blood draw to each woman as defined by her baseline factors,
and better define the CA125 level above which a screening intervention would be indicated.
The cut-point for any sub-group defined by a combination of factors was estimated from the
reference group cut-point modified by the cumulative percentage change for these factors, as
illustrated above for a current smoker with previous use of fertility drugs. An individualized
cut-point could improve the interpretation of the first CA125 test in ROCA based studies
when no longitudinal values are available. For subsequent CA125 tests, ROCA relies on
comparison with the baseline CA125 for each woman, which is less precisely defined when
there are only few previous CA125 values. Further analyses along the lines presented herein
should improve prediction of the woman’s CA125 baseline by accounting for menopausal
status, race, and other factors identified in this study, and thereby improve ROCA when a
woman’s baseline is still being established.
The multivariate linear model identified race (black, Asian), irregular periods, oral
contraceptive use, bilateral oophorectomy, and history of fertility treatment as important
factors worthy of consideration when interpreting a CA125 measurement, particularly in the
context of an ovarian cancer screening trial. External support of most factors identified by
our study that predict the CA125 distribution in high risk postmenopausal women derives
from a UK study(12) of normal risk postmenopausal women identifying the same or
similarly defined factors. Caution needs to be exercised for sub-groups with significant
effects but small sample sizes e.g. premenopausal Asian race n=35. Two other factors
related to age, namely age at menopause and current age had statistically significant effects
but had only minor clinical impact.
It is important to remember though that efficacy of screening in a high risk population has
not yet been demonstrated. Results from this large US based study as well as a similar study
in the UK will provide estimates for the sensitivity personalized CA125 cut-points and of
ROCA for early stage disease in high risk women. Until these trials report their final results,
there are currently no convincing data to suggest that any screening strategy is associated
with a significant reduction in ovarian cancer mortality or shift to early stage disease,
including the study reported herein, and that RRSO is currently considered the most
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effective risk reducing strategy. (14, 15) Should a woman choose screening despite the lack
of evidence demonstrating benefit relative to these final endpoints, the interpretation of ad-
hoc CA125 tests may still be guided by this discussion of CA125 98th percentile cut-points.
The significantly lower threshold in women in the GOG study cohort compared with those
in the CGN cohort (for GOG versus CGN: 48 versus 52 U/mL in premenopausal women and
31 versus 36 U/mL in the postmenopausal women) was an unanticipated finding in this
analysis. Both studies used the same eligibility criteria and procedures for handling,
processing and shipping blood samples were standardized. CA125 values were measured in
the same laboratory. One possible explanation for this effect could be unrecognized
differences between populations accrued through an oncology clinical trials oncology group
(GOG) versus those accrued by epidemiological registries, from which a large segment of
the CGN population was recruited. Because of this difference in CA125 cut-points between
the CGN and GOG cohorts, the multivariate models described in Table 2 were fitted
separately in the two cohorts. The variables in the model had a comparable effect (i.e. same
direction of the change in CA125, and to a comparable extent) in the separate analyses,
supporting the estimates of effects listed in Table 2 on predicted CA125 levels from the
analysis of the combined data from these two cohorts. A second possible contributing factor
is the GOG trial started 2 years later resulting in a differential due to the upgrade of the
immunoanalyzer. The consistency between the separate analyses may indicate that CA125
effects are more reliably estimated than percentiles. Clearly as these large ovarian cancer
screening studies in high risk women have indicated, there are many women who may
choose not to undergo RRSO at the current time. If ovarian cancer screening is considered,
our analysis may provide a more refined, individualized approach to interpreting a CA125
test rather than simply applying one threshold of 35 U/mL. In our study premenopausal
women have a significantly higher cut-point of 50 U/mL compared with the standard 35 U/
mL for postmenopausal women, and 40 U/mL for premenopausal women on OC. This study
lays the groundwork for personalizing the CA125 test in a prospective screening trial in high
risk women. This is a step towards the ultimate goal that integrates epidemiologic, genetic,
and longitudinal biomarker results into a subject specific screening algorithm.
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